SPERANZA project: HPV vaccination after treatment for CIN2+

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

Nubia Muñóz, Ricardo Manalastas, Punee Pitisuttithum et al. · The Lancet · 2009 · 480 citations

Veterinary Medicine, Immunology, Oncology +12

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

Elmar A. Joura, Suzanne M. Garland, Jorma Paavonen et al. · BMJ · 2012 · 316 citations · Full text

Medicine, Gynecology, Infectious Diseases +16

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)?

Woo Dae Kang, Ho Sun Choi, Seok Mo Kim · Gynecologic Oncology · 2013 · 228 citations · Full text

Medicine, Oncology, Surgery +17

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Sven-Eric Olsson, Susanne K. Kjær, Kristján Sigurðsson et al. · Human Vaccines · 2009 · 218 citations · Full text

Medicine, Immunology, Preventive Medicine +17

Prevention of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent Cohort Study

Kristin A. Swedish, S. H. Factor, Stephen E. Goldstone · Clinical Infectious Diseases · 2012 · 195 citations · Full text

Medicine, Oncology, Preventive Medicine +17